ATE378423T1 - Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie - Google Patents

Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie

Info

Publication number
ATE378423T1
ATE378423T1 AT00958530T AT00958530T ATE378423T1 AT E378423 T1 ATE378423 T1 AT E378423T1 AT 00958530 T AT00958530 T AT 00958530T AT 00958530 T AT00958530 T AT 00958530T AT E378423 T1 ATE378423 T1 AT E378423T1
Authority
AT
Austria
Prior art keywords
hpxr
cyp3a7
cyp3a4
vectors
proteins
Prior art date
Application number
AT00958530T
Other languages
English (en)
Inventor
Leszek Wojnowski
Elisabeth Hustert
Original Assignee
Epidauros Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie Ag filed Critical Epidauros Biotechnologie Ag
Application granted granted Critical
Publication of ATE378423T1 publication Critical patent/ATE378423T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00958530T 1999-09-10 2000-09-08 Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie ATE378423T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118120A EP1088900A1 (de) 1999-09-10 1999-09-10 Polymorphismen des menschlichen CYP3A4, CYP3A7 und hPXR Gene, und ihre Anwendung in Diagnose und Therapie

Publications (1)

Publication Number Publication Date
ATE378423T1 true ATE378423T1 (de) 2007-11-15

Family

ID=8238983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958530T ATE378423T1 (de) 1999-09-10 2000-09-08 Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie

Country Status (9)

Country Link
US (2) US7655771B1 (de)
EP (3) EP1088900A1 (de)
JP (2) JP2003509063A (de)
AT (1) ATE378423T1 (de)
AU (2) AU7513300A (de)
CA (2) CA2379541A1 (de)
DE (1) DE60037126T2 (de)
NO (2) NO20021146L (de)
WO (2) WO2001020025A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP362898A0 (en) 1998-05-21 1998-06-11 University Of Sydney, The Xenobiotic induction of gene expression
AUPR116100A0 (en) 2000-11-01 2000-11-23 University Of Sydney, The P450 gene regulation
WO2002044213A1 (en) * 2000-11-28 2002-06-06 Zaphiropoulos Peter G New cytochrome p450 proteins and the corresponding dna sequences
WO2002088305A2 (en) 2001-04-12 2002-11-07 Xenogen Corporation Isolation and identification of mouse and human transcription control elements associated with cytochrome expression
JP2003304896A (ja) * 2002-04-15 2003-10-28 Yasushi Yamazoe ヒトｃｙｐ３ａ誘導能の測定法
JP2006503883A (ja) * 2002-10-28 2006-02-02 ファルマシア・イタリア・エス・ピー・エー ネモルビシンの治療効果を最適化するための方法
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
JP2007119359A (ja) * 2005-10-25 2007-05-17 Fujifilm Corp 癌抑制剤
US9539593B2 (en) * 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
AU2010229772A1 (en) * 2009-03-26 2011-10-27 The Ohio State University Research Foundation Polymorphism in CYP3A4 gene affecting drug metabolizing and uses thereof
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) * 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
JP3564579B2 (ja) * 1994-05-06 2004-09-15 大塚製薬株式会社 ヒトチトクロームｐ４５０２ｄ６遺伝子多型の検出方法
FR2733251B1 (fr) * 1995-04-18 1997-07-04 Inst Nat Sante Rech Med Depistage du glaucome juvenile
US6025131A (en) * 1996-10-23 2000-02-15 E. I. Du Pont De Namours And Company Facile method for identifying regulated promoters
WO1998020165A2 (en) * 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Biallelic markers
WO1999005292A1 (en) 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Method for gene screening with the use of nuclear receptors
US6432639B1 (en) * 1997-09-10 2002-08-13 Dna Sciences Laboratories, Inc. Isolated CYP3A4 nucleic acid molecules and detection methods
AU3211699A (en) * 1998-03-27 1999-10-18 Glaxo Group Limited Orphan nuclear receptor
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US6183963B1 (en) 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay

Also Published As

Publication number Publication date
AU7001800A (en) 2001-04-17
NO20021147L (no) 2002-05-03
DE60037126T2 (de) 2008-09-18
EP1088900A1 (de) 2001-04-04
US7122652B1 (en) 2006-10-17
US7655771B1 (en) 2010-02-02
DE60037126D1 (de) 2007-12-27
WO2001020026A3 (en) 2001-12-13
WO2001020025A2 (en) 2001-03-22
WO2001020025A3 (en) 2001-10-11
EP1210462B1 (de) 2007-11-14
JP2003509064A (ja) 2003-03-11
CA2379541A1 (en) 2001-03-22
NO20021146D0 (no) 2002-03-07
CA2381066A1 (en) 2001-03-22
NO20021147D0 (no) 2002-03-07
NO20021146L (no) 2002-04-15
WO2001020026A2 (en) 2001-03-22
JP2003509063A (ja) 2003-03-11
AU7513300A (en) 2001-04-17
EP1210462A2 (de) 2002-06-05
EP1210463A2 (de) 2002-06-05

Similar Documents

Publication Publication Date Title
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
ATE371738T1 (de) Mittel und verfahren zur diagnose und behandlung affektiver störungen
EP1581656A4 (de) MODULATION DER EXPRESSION VON HIF1a UND HIF2a
ATE475432T1 (de) Arzneimittel für herzversagen
WO2005067391A3 (en) Diagnostic test for parkinson's disease
ATE378423T1 (de) Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie
EP1100547A4 (de) Zusammensetzungen und verfahren für die behandlung und diagnose von herzgefässerkrankungen.
DE60036487D1 (de) Polymorphismus im humanen mdr-1 gen und dessen verwendung
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
DE60140934D1 (de) Polymorphismen des humanen cyp2b6 gens und deren verwendung in diagnostischen und therapeutischen anwendungen
DE50312502D1 (de) Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen
WO2005014804A3 (en) Ubiquitin-specific protease
WO2003061573A3 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
ATE333504T1 (de) Polymorphismen in der promoterregion des humanen cyp2d6 gens und deren diagnostische und therapeutische verwendung
WO2005003288A3 (en) Diagnostic methods , prognostic methods and pharmaceutical compositions for neurodegenerative diseases like alzheimer’s disease by modulating and investigating genes rgs4 and itpkb, their gene products or fragments and derivatives thereof
WO2003087408A3 (en) Schizophrenia associated genes
Pal et al. High content live profiling reveals concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis
WO2005054426A3 (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
DE602004024300D1 (de) Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
WO2003039341A3 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
SE0303268D0 (sv) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties